TNF receptor 2 pathway: drug target for autoimmune diseases

Related Experiment Video

Updated: Jun 12, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

Denise Faustman1, Miriam Davis

  • 1Immunobiology Laboratory, Room 3602, Building 149, Massachusetts General Hospital and Harvard Medical School, 13th Street, Charlestown, Massachusetts 02129, USA. faustman@helix.mgh.harvard.edu

Nature Reviews. Drug Discovery
|May 22, 2010
PubMed

Insights

New therapies for autoimmune diseases aim to selectively destroy harmful T lymphocytes. Activating tumour necrosis factor receptor 2 (TNFR2) offers a targeted approach, potentially reducing side effects of current treatments.

Area of Science:

  • Immunology
  • Autoimmune Diseases
  • Drug Development

Background:

  • Current autoimmune disease therapies often cause adverse effects by damaging healthy cells alongside pathological ones.
  • Existing treatments lack targeted strategies to eliminate specific autoreactive immune cells responsible for autoimmune attacks.
  • The need for safer, more effective treatments for autoimmune conditions is critical.

Purpose of the Study:

  • To introduce a novel therapeutic strategy for autoimmune diseases.
  • To explore the selective destruction of autoreactive immune cells via targeted approaches.
  • To evaluate the potential of tumour necrosis factor receptor 2 (TNFR2) activation in autoimmune therapy.

Main Methods:

  • Review of emerging research on targeted autoimmune therapies.
  • Analysis of TNFR2 expression on autoreactive and normal T lymphocytes.
  • Investigation of TNFR2-specific activation as a therapeutic mechanism.

Main Results:

  • TNFR2 is expressed on both autoreactive and normal T lymphocytes.
  • Selective activation of TNFR2 presents a potential method for targeting autoreactive cells.
  • This approach may lead to reduced toxicity compared to current therapies.

Conclusions:

  • Targeted activation of TNFR2 is a promising strategy for autoimmune disease treatment.
  • This approach holds the potential to improve safety and efficacy by sparing healthy cells.
  • Further research into TNFR2-mediated therapies could revolutionize autoimmune disease management.

More Related Videos

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice

Published on: January 31, 2020

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...